Neurocrine Biosciences (NBIX) Profit After Tax (2010 - 2026)

Neurocrine Biosciences' Profit After Tax history runs 17 years deep, the most recent figure standing at $197.9 million for Q1 2026.

• Quarterly Profit After Tax rose 1682.88% year-over-year to $197.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $676.6 million (up 125.31% YoY) and the FY2025 annual result came in at $485.9 million, up 42.87% from the prior year.
• Profit After Tax was $197.9 million for Q1 2026 at Neurocrine Biosciences, up from $161.0 million in the prior quarter.
• Across five years, Profit After Tax topped out at $210.2 million in Q3 2025 and bottomed at -$76.6 million in Q1 2023.
• A 5-year average of $84.1 million and a median of $85.7 million in 2022 frame the typical range for Profit After Tax.
• Annual changes were most pronounced in 2023 — Profit After Tax slumped 651.08% — and 2026, when it soared 1682.88%.
• Neurocrine Biosciences' Profit After Tax stood at $85.7 million in 2022, then jumped by 89.73% to $162.6 million in 2023, then plunged by 41.94% to $94.4 million in 2024, then surged by 70.55% to $161.0 million in 2025, then increased by 22.92% to $197.9 million in 2026.
• Business Quant data shows NBIX's Profit After Tax at $197.9 million in Q1 2026, $161.0 million in Q4 2025, and $210.2 million in Q3 2025.